The new chair of the ACR’s Government Affairs Committee, Dr. Downey says physicians play a vital role in helping policymakers understand how policies and laws affect patients and the practice of rheumatology.
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…
Big Utilization Management Reform Wins in Pennsylvania, Massachusetts
Prior authorization and step therapy reform bills recently enacted in Pennsylvania and Massachusetts offer case studies into how substantive policy change can take persistence, patience and a bipartisan approach to achieve success.
From Denial of Spondyloarthritis to a Support Group Leader & Medical Doctor of Rheumatology: A Patient’s Perspective
PHILADELPHIA—“My symptoms started in the final year of medical school, and at that stage I believed I was strong enough to fight my condition,” said Shung Ming Chiu, MD, in a poster presentation at ACR Convergence 2022. “Later, I realized that it’s not [about] fighting [but] rather accepting it and adapting to the new normal….
Is Gout an Autoinflammatory Syndrome After All?
PHILADELPHIA—The term autoinflammatory syndrome was coined by Daniel L. Kastner, MD, PhD, National Institutes of Health (NIH), Bethesda, Md., not long after he discovered that mutations in the gene MEFV, which codes for the protein pyrin, are responsible for familial Mediterranean fever (FMF).1 Early on, the term was meant to signify monogenic conditions in which…
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
ACR Scores Wins for Rheumatology Community at AMA House of Delegates Interim Meeting
Key successes for the rheumatology community secured by the ACR’s delegation include passage of the ACR’s resolution addressing pharmacy benefit administrators, advances in policies to protect rheumatologists and patients in the post-Dobbs landscape and retention of the rheumatology’s representation in the AMA House of Delegates.
Elevated BMI Associated with Pain in Patients with Hand OA
Research from Gloersen et al. suggests the systemic effects of obesity, as measured by leptin, may play a role in the severity of pain experienced by patients with hand osteoarthritis.
Self-Initiated Care May Reduce Workforce Gap
Seppen et al. developed a smartphone application for patients with RA to assess the safety and efficacy of patient-initiated care, compared with usual care. By answering a weekly Routine Assessment of Patient Index Data 3 (RAPID3) questionnaire, patients were able to monitor their own disease activity between clinic visits.
November, a Busy Month for RheumPAC
In November, RheumPAC will be leading its annual matching campaign and hosting two events at ACR Convergence 2022. Thanks to matching donors, every contribution in November will be amplified.
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 308
- Next Page »